TORONTO, March 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that it will release its financial and operational results for the quarter and year ended December 31, 2025, after financial markets close on March 24, 2026. The Company's fourth fiscal quarter and year end 2025 financial and operational results will be available on SEDAR+, EDGAR, and on the Company's website at https://www.quantumbiopharma.com/investors.
Private Placement Offering
The Company also announces that it intends to complete a non-brokered private placement offering (the "Offering") of up to 4,000 convertible debenture units (the "Debenture Units") of the Company at a price of $1,000 per Debenture Unit.
Each Debenture Unit will consist of (i) one secured convertible debenture having a face value of $1,000.00 (each a "Debenture"); and (ii) 250 common share purchase warrants (each a "Warrant") exercisable for 250 Class B subordinate voting shares in the Company (each, a "Share"). The Debentures will mature on the date that is 24 months from the date of issuance (the "Maturity Date") and shall bear interest at a rate of 1.25% per month, beginning on the date of issuance and payable in cash on the last day of each calendar quarter, starting June 30, 2026.
The principal sum of the Debentures, or any portion thereof, and any accrued but unpaid interest, may be converted into Shares at a conversion price of $4.00 per Share (the "Conversion Price"). Each Warrant shall entitle the holder to acquire one additional Share (each, a "Warrant Share") at a price of $5.00 per Warrant Share, for a period of five (5) years from the date of issuance.
The Company will use the proceeds from the Offering for the ongoing development of the Company's business model and for general working capital purposes.
Debt Settlement
The Company also announces that it intends to settle certain amounts owing to arm's length creditors and insiders of the Company (collectively, the "Creditors") through the issuance of Shares at a deemed price per Share equal to the Conversion Price (the "Debt Settlement").
The participation by insiders ...
